EE200200049A - Polümorfismid inimese MDR-1 geenis ning nende kasutamine diagnostikas ja terapeutilistes rakendustes - Google Patents
Polümorfismid inimese MDR-1 geenis ning nende kasutamine diagnostikas ja terapeutilistes rakendustesInfo
- Publication number
- EE200200049A EE200200049A EEP200200049A EEP200200049A EE200200049A EE 200200049 A EE200200049 A EE 200200049A EE P200200049 A EEP200200049 A EE P200200049A EE P200200049 A EEP200200049 A EE P200200049A EE 200200049 A EE200200049 A EE 200200049A
- Authority
- EE
- Estonia
- Prior art keywords
- mdr
- vectors
- proteins
- polynucleotides
- gene
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 9
- 102000054765 polymorphisms of proteins Human genes 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 102000040430 polynucleotide Human genes 0.000 abstract 5
- 108091033319 polynucleotide Proteins 0.000 abstract 5
- 239000002157 polynucleotide Substances 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 239000013598 vector Substances 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 206010059866 Drug resistance Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000007257 malfunction Effects 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000009261 transgenic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99114938 | 1999-07-30 | ||
| EP00103361 | 2000-02-22 | ||
| PCT/EP2000/007314 WO2001009183A2 (en) | 1999-07-30 | 2000-07-28 | Polymorphisms in the human mdr-1 gene and applications thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EE200200049A true EE200200049A (et) | 2003-04-15 |
Family
ID=26070560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP200200049A EE200200049A (et) | 1999-07-30 | 2000-07-28 | Polümorfismid inimese MDR-1 geenis ning nende kasutamine diagnostikas ja terapeutilistes rakendustes |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20050227249A1 (et) |
| EP (1) | EP1232260B1 (et) |
| JP (2) | JP2003510021A (et) |
| KR (1) | KR100814188B1 (et) |
| AT (1) | ATE373710T1 (et) |
| AU (1) | AU1131901A (et) |
| BG (1) | BG65988B1 (et) |
| CA (2) | CA2697207A1 (et) |
| CZ (1) | CZ2002329A3 (et) |
| DE (1) | DE60036487T2 (et) |
| DK (1) | DK1232260T3 (et) |
| EE (1) | EE200200049A (et) |
| ES (1) | ES2292481T3 (et) |
| HR (1) | HRP20020093B1 (et) |
| HU (1) | HUP0201997A3 (et) |
| MX (1) | MXPA02001094A (et) |
| NO (2) | NO330680B1 (et) |
| PL (1) | PL354034A1 (et) |
| SK (1) | SK1502002A3 (et) |
| WO (1) | WO2001009183A2 (et) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2430269A1 (en) * | 2000-11-29 | 2002-06-06 | Epidauros Biotechnologie Ag | Methods for diagnosing individuals with an increased risk to develop a deficiency based on mdr1 gene polymorphism |
| AU2001231550A1 (en) * | 2000-11-29 | 2002-06-11 | Epidauros Biotechnologie Ag | Use of mdr-1 inducers for treating or preventing diseases |
| ATE449184T1 (de) | 2001-01-12 | 2009-12-15 | Univ Washington | Mdr1-varianten und verfahren zu ihrer verwendung |
| WO2003025174A2 (en) * | 2001-09-06 | 2003-03-27 | Bayer Healthcare Ag | Regulation of human mrp1-like protein |
| EP1340818A1 (en) * | 2002-02-27 | 2003-09-03 | Epigenomics AG | Method and nucleic acids for the analysis of a colon cell proliferative disorder |
| AU2003280867A1 (en) * | 2002-11-04 | 2004-06-07 | Charite-Universitatsme Dizin Berlin | Specific haplotypes of the mdr1 gene and their use in diagnosis and therapy |
| DK1756310T3 (da) * | 2004-05-12 | 2013-03-18 | Max Planck Gesellschaft | Fremgangsmåde til at påvise polymorfi i ABCB1-genet associeret med mangel af respons for et CNS-aktivt lægemiddel samt lægemiddel omfattende en ABCB1-inhibitor til anvendelse i behandlingen af CNS-relaterede sygdomme |
| WO2006133841A1 (en) * | 2005-06-13 | 2006-12-21 | F. Hoffmann-La Roche Ag | MDRl SNP IN ACUTE RETECTION |
| WO2006133842A1 (en) * | 2005-06-13 | 2006-12-21 | F.Hoffmann-La Roche Ag | Impdh2 snp associated with acute rejection |
| US20090286234A1 (en) * | 2005-06-13 | 2009-11-19 | Laurent Essioux | Il10 snp associated with acute rejection |
| EP1957673A2 (en) * | 2005-11-10 | 2008-08-20 | Government of the United States of America, Represented by the Secretary, Department of Health and Human Services | Materials and methods for abcb1 polymorphic variant screening, diagnosis, and treatment |
| EP2520670B1 (en) | 2007-06-12 | 2014-02-26 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | New polymorphisms in ABCB1 associated with a lack of clinical response to medicaments |
| KR101033840B1 (ko) * | 2011-03-08 | 2011-05-16 | (주)제일엔지니어링건축사사무소 | 공동주택용 입상관 연결구조 |
| CA3067642A1 (en) * | 2017-06-19 | 2018-12-27 | Jungla Llc | Interpretation of genetic and genomic variants via an integrated computational and experimental deep mutational learning framework |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| CA1284931C (en) * | 1986-03-13 | 1991-06-18 | Henry A. Erlich | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
| US5206352A (en) * | 1986-03-28 | 1993-04-27 | Board Of Trustees Of The University Of Illinois | Compositions for clones containing DNA sequences associated with multidrug resistance in human cells |
| US5928637A (en) * | 1987-06-16 | 1999-07-27 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods of inducing multidrug resistance using human MDR1 cDNA |
| US5851819A (en) * | 1987-06-16 | 1998-12-22 | National Institutes Of Health | Vectors carrying MDR1 cDNA which confer multidrug resistance on transduced cells |
| JPH02100680A (ja) * | 1988-10-05 | 1990-04-12 | Suntory Ltd | ヒト正常細胞由来ｍｄｒ関連遺伝子 |
| US5399483A (en) * | 1989-03-30 | 1995-03-21 | Suntory Limited | Expression of MDR-related gene in yeast cell |
| US5856104A (en) * | 1996-10-28 | 1999-01-05 | Affymetrix, Inc. | Polymorphisms in the glucose-6 phosphate dehydrogenase locus |
| US5830697A (en) * | 1997-01-21 | 1998-11-03 | The Board Of Trustees Of The Leland Stanford Junior University | P-glycoprotein mutant resistant to cyclosporin modulation |
-
2000
- 2000-07-28 PL PL00354034A patent/PL354034A1/xx unknown
- 2000-07-28 MX MXPA02001094A patent/MXPA02001094A/es active IP Right Grant
- 2000-07-28 AT AT00972654T patent/ATE373710T1/de active
- 2000-07-28 CA CA2697207A patent/CA2697207A1/en not_active Abandoned
- 2000-07-28 DK DK00972654T patent/DK1232260T3/da active
- 2000-07-28 KR KR1020027001248A patent/KR100814188B1/ko not_active IP Right Cessation
- 2000-07-28 JP JP2001513989A patent/JP2003510021A/ja active Pending
- 2000-07-28 WO PCT/EP2000/007314 patent/WO2001009183A2/en active IP Right Grant
- 2000-07-28 EE EEP200200049A patent/EE200200049A/et unknown
- 2000-07-28 AU AU11319/01A patent/AU1131901A/en not_active Abandoned
- 2000-07-28 SK SK150-2002A patent/SK1502002A3/sk unknown
- 2000-07-28 ES ES00972654T patent/ES2292481T3/es not_active Expired - Lifetime
- 2000-07-28 HU HU0201997A patent/HUP0201997A3/hu unknown
- 2000-07-28 CZ CZ2002329A patent/CZ2002329A3/cs unknown
- 2000-07-28 EP EP00972654A patent/EP1232260B1/en not_active Expired - Lifetime
- 2000-07-28 DE DE60036487T patent/DE60036487T2/de not_active Expired - Lifetime
- 2000-07-28 CA CA2376666A patent/CA2376666C/en not_active Expired - Lifetime
-
2002
- 2002-01-29 BG BG106362A patent/BG65988B1/bg unknown
- 2002-01-29 NO NO20020470A patent/NO330680B1/no not_active IP Right Cessation
- 2002-01-30 HR HR20020093A patent/HRP20020093B1/xx not_active IP Right Cessation
-
2004
- 2004-10-14 US US10/965,348 patent/US20050227249A1/en not_active Abandoned
-
2010
- 2010-06-02 NO NO20100798A patent/NO20100798L/no unknown
-
2011
- 2011-01-24 JP JP2011011834A patent/JP2011142909A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CZ2002329A3 (cs) | 2002-07-17 |
| WO2001009183A2 (en) | 2001-02-08 |
| HUP0201997A2 (en) | 2002-09-28 |
| DE60036487D1 (de) | 2007-10-31 |
| EP1232260A2 (en) | 2002-08-21 |
| CA2697207A1 (en) | 2001-02-08 |
| DK1232260T3 (da) | 2008-02-04 |
| KR20020059347A (ko) | 2002-07-12 |
| NO330680B1 (no) | 2011-06-06 |
| AU1131901A (en) | 2001-02-19 |
| HRP20020093A2 (en) | 2004-06-30 |
| WO2001009183A3 (en) | 2002-03-28 |
| EP1232260B1 (en) | 2007-09-19 |
| ATE373710T1 (de) | 2007-10-15 |
| HRP20020093B1 (en) | 2011-02-28 |
| SK1502002A3 (en) | 2002-07-02 |
| NO20100798L (no) | 2002-03-26 |
| PL354034A1 (en) | 2003-12-15 |
| JP2011142909A (ja) | 2011-07-28 |
| JP2003510021A (ja) | 2003-03-18 |
| US20050227249A1 (en) | 2005-10-13 |
| CA2376666A1 (en) | 2001-02-08 |
| BG106362A (bg) | 2002-09-30 |
| NO20020470D0 (no) | 2002-01-29 |
| CA2376666C (en) | 2010-05-25 |
| NO20020470L (no) | 2002-03-26 |
| DE60036487T2 (de) | 2008-06-19 |
| BG65988B1 (bg) | 2010-08-31 |
| HUP0201997A3 (en) | 2005-01-28 |
| ES2292481T3 (es) | 2008-03-16 |
| MXPA02001094A (es) | 2003-07-21 |
| KR100814188B1 (ko) | 2008-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE200200049A (et) | Polümorfismid inimese MDR-1 geenis ning nende kasutamine diagnostikas ja terapeutilistes rakendustes | |
| BRPI0510206A (pt) | método de identificação de fenótipo, célula isolada, métodos de identificação de agentes, agentes, agentes terapêuticos, método de avaliação de agente terapêutico, composição farmacêutica, métodos de tratamento, prevenção ou melhoria de disfunções e métodos de modulação | |
| WO2004053079A3 (en) | Compositions, splice variants and methods relating to ovarian specific genes and proteins | |
| NZ531570A (en) | DNA sequences for human angiogenesis genes | |
| WO2001020026A3 (en) | POLYMORPHISMS IN THE HUMAN hPXR GENE AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | |
| Chang et al. | rAAV-CRISPRa therapy corrects Rai1 haploinsufficiency and rescues selective disease features in Smith-Magenis syndrome mice | |
| Pang et al. | High-throughput sequencing offers new insights into 5-hydroxymethylcytosine | |
| WO2004053075A3 (en) | Compositions, splice variants and methods relating to breast specific genes and proteins | |
| WO2004050860A3 (en) | Compositions, splice variants and methods relating to colon specific genes and proteins | |
| AU3925701A (en) | Polymorphisms in the human cyp2b6 gene and their use in diagnostic and therapeutic applications | |
| WO2004013311A3 (en) | Compositions and methods relating to ovarian specific genes and proteins | |
| Boylan et al. | Targeting Progranulin as an Immuno-Neurology Therapeutic Approach | |
| WO2004050858A3 (en) | Compositions, splice variants and methods relating to colon specific genes and proteins | |
| Holcomb et al. | GRHD PLANNING COMMITTEE | |
| DE50312502D1 (de) | Screeningverfahren zum identifizieren protektiver substanzen für die behandlung neurodegenerativer und/oder ischämischer erkrankungen | |
| WO2004052290A3 (en) | Compositions, splice variants and methods relating to breast specific genes and proteins | |
| WO2004053077A3 (en) | Compositions,splice variants and methods relating to breast specific genes and proteins | |
| WO2003020953A3 (en) | Compositions and methods relating to colon specific genes and proteins | |
| Neumeister et al. | Serotonin-1B receptor imaging in PTSD | |
| WO2003060121A3 (en) | Compositions and methods relating to gastric specific genes and proteins | |
| ATE541040T1 (de) | Pim-3 kinase als ziel für type 2 diabetes mellitus | |
| NAFEA et al. | Study of Vascular Endothelial Growth Factor Gene Polymorphism in Acute Myeloid Leukemia Patients | |
| WO2005005647A3 (en) | Compositions, splice variants and methods relating to ovarian specific genes and proteins | |
| WO2003060145A3 (en) | Compositions and methods relating to pancreatic specific genes and proteins | |
| WO2005044075A3 (en) | Compositions, splice variants and methods relating to breast specific genes and proteins |